Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 63

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 63
---
 fair value:As of September 30, 2025:(in thousands)Level 1Level 2Level 3TotalCash equivalents:Money market funds$— $53,842 $— $53,842 Corporate debt securities— 11,308 — 11,308 U.S. Treasury and government securities— 5,780 — 5,780 Short-term investments:U.S. Treasury and government securities— 95,781 — 95,781 Corporate debt securities— 41,249 — 41,249 Related party short-term investment:Beam equity securities4,861 — — 4,861 Total cash equivalents and investments$4,861 $207,960 $— $212,821 As of December 31, 2024:(in thousands)Level 1Level 2Level 3TotalCash equivalents:Money market funds$— $178,212 $— $178,212 Corporate debt securities— 3,793 — 3,793 Short-term investment:U.S. Treasury and government securities— 2,998 — 2,998 Related party short-term investment:Beam equity securities4,968 — — 4,968 Total cash equivalents and investments$4,968 $185,003 $— $189,971 The Company classifies its investments as short-term based on each instrument’s underlying contractual maturity date. The fair value of investments classified as Level 2 are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. 

14

Investments in Debt SecuritiesUnrealized gains and losses of investments in debt securities consisted of the following: As of September 30, 2025:(in thousands)Amortized CostUnrealized GainsUnrealized LossesFair ValueShort-term investments in debt securities:U.S. Treasury and government securities$95,744 $38 $(1)$95,781 Corporate debt securities41,253 2 (6)41,249 Total short-term investments in debt securities$136,997 $40 $(7)$137,030 As of December 31, 2024:(in thousands)Amortized CostUnrealized GainsUnrealized LossesFair ValueShort-term investments:U.S. Treasury and government securities$